Abstract
Cisplatin-related diarrhea is a relatively common complication in the clinical management of cancer patients and until now no treatment for this condition has been identified. Octreotide has been reported effective in the treatment of 5-fluorouracil-related diarrhea. To assess the safety and efficacy of octreotide in controlling diarrhea caused by cisplatin, 43 patients who had already had diarrhea during the 24-hour period following a previous cisplating administration were randomized to receive either octreotide or placebo during the next cisplatin course. The patients given octreotide experienced less diarrhea (5 vs. 75%, p = 0.01). There were no side effects. We conclude that octreotide is more effective than placebo in controlling diarrhea following cisplatin chemotherapy.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects*
-
Cisplatin / therapeutic use
-
Cyclophosphamide / administration & dosage
-
Diarrhea / chemically induced*
-
Diarrhea / drug therapy*
-
Double-Blind Method
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Head and Neck Neoplasms / drug therapy
-
Humans
-
Lung Neoplasms / drug therapy
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Mitomycin / administration & dosage
-
Octreotide / therapeutic use*
-
Ovarian Neoplasms / drug therapy
-
Placebos
-
Sarcoma / drug therapy
-
Soft Tissue Neoplasms / drug therapy
Substances
-
Placebos
-
Mitomycin
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Octreotide
-
Methotrexate